AN
Anixa Biosciences, Inc.
ANIX · NASDAQ
$2.76 -3.83% (-$0.11)
1M -20.92%
Market Cap $93.9M
P/E Ratio -
Div. Yield -
ROE 52.83%
Bulios Fair Price
$1.41
48.9% downside
Current Price
$2.76
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ANIX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
19 /100
Expensive P/B 6.49x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining Book val. growth 19.49%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 82.06%
ROE 52.83%
ROA 51.85%
Debt
100 /100
Low Debt/Equity 0.01x
Current ratio 8.54x
Int. coverage N/A
Stability
68 /100
Stable Beta 0.60x
EPS volatility 25.95%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ANIX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Amit Kumar
Employees
4
Headquarters
San Jose
Upcoming events
11 JAN
Earnings
Upcoming earnings report